This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

TIDES Europe: Oligonucleotide and Peptide Therapeutics

SAVINGS DEADLINE EXPIRES:

  • 00
    Days
  • 00
    Hrs
  • 00
    Mins
  • 00
    Secs
Delivered as Hybrid Event from 16-18 November 2022
Live In-Person Conference Delivered 16-18 NovemberAustria Center Vienna

Covadonga Paneda, PhD
Chief Development Officer at Altamira Therapeutics

Profile

Dr. Covadonga Pañeda, Ph.D. has over 15 years of experience in leadership and management of biotechnology companies acquired through various roles in drug development, contract research organizations and in the biotech venture capital sector in Europe. Before joining Altamira in April 2022, she spent seven years managing Sylentis S.A R&D efforts, a clinical stage RNAi biopharmaceutical company, two years leading the translational activities of newly founded companies in the academic sector including Isquaemia Biotech and Mirnax Biosens; and most recently, she served as Director of Development at LiMM Therapeutics, a neuroimmune biopharmaceutical company.

Dr. Pañeda holds a Ph.D. in Biochemistry and Molecular Biology from the Faculty of Medicine at Universidad Autónoma, Madrid, Spain, and a Master of Management of Biotechnology Companies awarded by Fundación Genoma España, Madrid, Spain.

Agenda Sessions

  • Overcoming Challenges To RNA Systemic Extrahepatic Delivery and Endosomal Escape With Peptide-Nucleotide Polyplexes

    09:15